Over the past 10 years, Thermo Fisher Scientific (TMO) earnings per share (EPS) grew 13.6% a year, revenue grew 10.1% a year and free cash flow grew 10.1% a year, with an average return on invested capital (ROIC) of 8.1%. TMO stock trades at $690.00, a P/E of 29.0, below its historical average of 33.0. Analysts' average 12-month price target is $664.79 (−3.7%).
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services.
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | 10.3% | 10.4% | 6.3% | B |
| EPS GrowthEPS | 13.6% | 2.0% | 8.9% | C+ |
| Revenue GrowthRevenue | 10.1% | 6.7% | 7.2% | C+ |
| Cash Flow GrowthCash Flow | 10.1% | -1.6% | 18.6% | B |
| ROICROIC | 8.1% | 8.7% | 7.6% | B |
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $53.12 | $54.20 | $63.85 | $67.95 | $73.64 | $86.48 | $102.75 | $111.62 | $120.45 | $129.46 | $141.66 | $141.99 | |
| Basic EPSEPS | $4.96 | $5.12 | $5.64 | $7.31 | $9.24 | $16.10 | $19.61 | $17.73 | $15.53 | $16.58 | $17.77 | $23.83 | |
| RevenueRevenue | $16,965,400,000 | $18,274,100,000 | $20,918,000,000 | $24,358,000,000 | $25,542,000,000 | $32,218,000,000 | $39,211,000,000 | $44,915,000,000 | $42,857,000,000 | $42,879,000,000 | $44,557,000,000 | $46,336,000,000 | |
| Free Cash FlowCash Flow | $2,394,000,000 | $2,711,900,000 | $3,497,000,000 | $3,785,000,000 | $4,047,000,000 | $6,815,000,000 | $7,020,000,000 | $6,911,000,000 | $6,927,000,000 | $7,267,000,000 | $6,293,000,000 | $7,318,000,000 | |
| ROIC (%)ROIC | 6.6% | 6.6% | 5.8% | 6.8% | 7.3% | 11.3% | 10.7% | 9.0% | 8.0% | 8.0% | 7.6% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
43 firms rate it — 36 buy, 7 hold · Most recent Oct 2026
The average 12-month analyst price target for TMO is $664.79, with a range of $520.00 to $750.00. That is −3.7% from the current price of $690.00.
Most rate it a buy. Of 43 firms covering Thermo Fisher Scientific, the ratings are 36 buy or strong buy, 7 hold and 0 sell or strong sell.
Annual growth rates for TMO. EPS: 13.6% over 10 years, 2.0% over 5 years, 8.9% over 1 year. Revenue: 10.1% over 10 years, 6.7% over 5 years, 7.2% over 1 year. Free cash flow: 10.1% over 10 years, -1.6% over 5 years, 18.6% over 1 year. Book value per share: 10.3% over 10 years, 10.4% over 5 years, 6.3% over 1 year.
Thermo Fisher Scientific's return on invested capital (ROIC) was 7.6% in fiscal 2025. Its 10-year average ROIC is 8.1%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
TMO's current P/E ratio is 29.0, compared with a historical average of 33.0. Trailing earnings per share are $23.83.
TMO last traded at $690.00 as of October 19, 2026. Its 52-week range is $435.27 to $704.00. Thermo Fisher Scientific has a market cap of $255.13B.
Data as of October 19, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.